We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Prognostic Factors in Children with HLH Investigated

By LabMedica International staff writers
Posted on 27 Oct 2016
Image: A photomicrograph of a bone marrow showing stromal macrophages containing numerous red blood cells in their cytoplasm from a patient with hemophagocytic lymphohistiocytosis (Photo courtesy of Nephron).
Image: A photomicrograph of a bone marrow showing stromal macrophages containing numerous red blood cells in their cytoplasm from a patient with hemophagocytic lymphohistiocytosis (Photo courtesy of Nephron).
Hemophagocytic lymphohistiocytosis (HLH) is a rare disease characterized by a rapidly fatal hematological disorder usually associated with malignancies and severe infections and it presents with prolonged high fever that could not be controlled by antibiotics.

Other manifestations of HLH are hepatosplenomegaly, cytopenia, widespread infiltration with lymphocytes, and benign-looking histiocytes with hemophagocytosis in the bone marrow, liver, spleen, or lymph nodes. Early diagnosis and combined treatment can effectively control this life-threatening disease.

Scientists at the Guangdong Medical College (Shenzhen, People’s Republic of China) carried out a retrospective analysis on HLH from January 1, 2000, to November 30, 2013. Of the 56 pediatric patients, 35 were boys and 21 were girls with a median age of 4.5 years (range: four months to 12 years) at the onset of HLH. The median duration before diagnosis of HLH was 1.5 weeks (range: one week to six weeks). The most common clinical symptoms observed were fever (100%), hepatomegaly or splenomegaly (95.24%), and pancytopenia (100%).

The team found that characteristic laboratory values presented with increased ferritin (64.29%), triglycerides (78.6%), transaminases (81%), bilirubin (67.5%), lactate dehydrogenase (95.2%), and decreased fibrinogen (61.9%), sodium (40.5%), and potassium (30.9%). Bone marrow aspiration showed hemophagocytosis in 48 cases (85.7%). Among the clinical and laboratory features analyzed, high lactate dehydrogenase (LDH) of greater than 2,000 U/L, high bilirubin of greater than 2 mg/mL, and younger age less than 2 years old at the time of diagnosis indicated worst outcome.

Anemia was observed in 39 patients (five cases with hemoglobin level less than 90 g/L, 27 cases less than 60–89 g/L, seven cases less than 30–59 g/L), neutropenia (neutrophil count less than 1.5×109/L) in 28 patients (22 cases less than 0.5–1.0×109/L, and five cases less than 0.5×109/L, and thrombocytopenia (platelet count less than 100×109/L) in 35 patients (33 cases with platelet count less than 20–99×109/L and two cases with platelet count less than 20×109/L). Examination of bone marrow aspiration showed hemophagocytosis in 48 (85.7%) patients.

The authors concluded that the etiology of HLH is complicated and early diagnosis is difficult. The level of LDH and bilirubin may predict the severity of HLH and depending on the clinical presentation, individualized therapy is needed for different patients. The study was published on October 11, 2016, in the Journal of Blood Medicine.

Related Links:
Guangdong Medical College


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
Manual Pipetting Aid
Pipette Controllers macro

Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
INTEGRA BIOSCIENCES AG